These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21175429)

  • 21. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
    Harris TK
    IUBMB Life; 2003 Mar; 55(3):117-26. PubMed ID: 12822887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells.
    Tamgüney T; Zhang C; Fiedler D; Shokat K; Stokoe D
    Exp Cell Res; 2008 Jul; 314(11-12):2299-312. PubMed ID: 18514190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel regulatory mechanism links PLCγ1 to PDK1.
    Raimondi C; Chikh A; Wheeler AP; Maffucci T; Falasca M
    J Cell Sci; 2012 Jul; 125(Pt 13):3153-63. PubMed ID: 22454520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517.
    Islam I; Brown G; Bryant J; Hrvatin P; Kochanny MJ; Phillips GB; Yuan S; Adler M; Whitlow M; Lentz D; Polokoff MA; Wu J; Shen J; Walters J; Ho E; Subramanyam B; Zhu D; Feldman RI; Arnaiz DO
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3819-25. PubMed ID: 17544272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based optimization of potent PDK1 inhibitors.
    Angiolini M; Banfi P; Casale E; Casuscelli F; Fiorelli C; Saccardo MB; Silvagni M; Zuccotto F
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4095-9. PubMed ID: 20621725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation.
    Biondi RM
    Trends Biochem Sci; 2004 Mar; 29(3):136-42. PubMed ID: 15003271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.
    Scortegagna M; Lau E; Zhang T; Feng Y; Sereduk C; Yin H; De SK; Meeth K; Platt JT; Langdon CG; Halaban R; Pellecchia M; Davies MA; Brown K; Stern DF; Bosenberg M; Ronai ZA
    Cancer Res; 2015 Apr; 75(7):1399-412. PubMed ID: 25712345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
    Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
    J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2.
    Kobayashi T; Cohen P
    Biochem J; 1999 Apr; 339 ( Pt 2)(Pt 2):319-28. PubMed ID: 10191262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new tool to dissect the function of p70 S6 kinase.
    Bilanges B; Vanhaesebroeck B
    Biochem J; 2010 Oct; 431(2):e1-3. PubMed ID: 20874709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions.
    Biondi RM; Nebreda AR
    Biochem J; 2003 May; 372(Pt 1):1-13. PubMed ID: 12600273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.
    Islam I; Bryant J; Chou YL; Kochanny MJ; Lee W; Phillips GB; Yu H; Adler M; Whitlow M; Ho E; Lentz D; Polokoff MA; Subramanyam B; Wu JM; Zhu D; Feldman RI; Arnaiz DO
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3814-8. PubMed ID: 17531483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
    Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PI3K-PDK1 connection: more than just a road to PKB.
    Vanhaesebroeck B; Alessi DR
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):561-76. PubMed ID: 10698680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting PDK1 in cancer.
    Raimondi C; Falasca M
    Curr Med Chem; 2011; 18(18):2763-9. PubMed ID: 21568903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphoinositide-dependent kinase 1 targets protein kinase A in a pathway that regulates interleukin 4.
    Nirula A; Ho M; Phee H; Roose J; Weiss A
    J Exp Med; 2006 Jul; 203(7):1733-44. PubMed ID: 16785309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein kinase Cdelta participates in insulin-induced activation of PKB via PDK1.
    Brand C; Cipok M; Attali V; Bak A; Sampson SR
    Biochem Biophys Res Commun; 2006 Oct; 349(3):954-62. PubMed ID: 16962999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines.
    El-Sheikh A; Fan R; Birks D; Donson A; Foreman NK; Vibhakar R
    Pediatr Blood Cancer; 2010 Jul; 55(1):35-41. PubMed ID: 20232424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.